Frontage continues build-out to meet late-stage developers demand

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/belchonock)
(Image: Getty/belchonock)

Related tags: Frontage Laboratories, Bioanalytical, Bioanalysis, cell and gene therapy

Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.

The addition of 10,000 square feet in its Exton, PA, laboratory space was announced​ by Frontage Laboratories in October 2019. At that point, the company stated that the expansion will enable enhancement of its capabilities in biologic drugs development.

Frontage has cut the ribbon​ at the facility, which now totals 80,000 square feet. This brings the bioanalytical capabilities additions completed during the past four months to 52,000 square feet, in an aim to support the booming R&D business of biologics.

This conclusion comes after the establishment​ of a 42,000 square foot laboratory in Shanghai, China, dedicated to bioanalytical services. Apart from its bioanalytical business, Frontage also has recently invested in scaling up its facility in New Jersey​, dedicated to nicotine-related studies.

Following the build-out completion, the facility in Exton is equipped with increased sample management and laboratory space, as well as enhanced instrumentation, systems, robotics automation, software and personnel capacity.

Frontage also has established a center of excellence supporting cell and gene therapies development at the location. The center includes dedicated laboratories in DNA/RNA sample preparation, polymerase chain reaction services, flow cytometry, and cell culture.

According to the company, the site now houses ‘greater’ biomarker, PK, and immunogenicity bioanalytical capacity, to support large clinical studies at Phase II-IV.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars